Infertility Clinical Trial
Official title:
A Randomized Controlled Trial of Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Predicted Low Responders
Patients who have undergone in vitro fertilization (IVF) and produced four or less follicles or had four or less oocytes (eggs) retrieved are often referred to as poor responders. We will refer to these patients from this point forward as "low responders" to avoid using a potentially offensive label. We are currently using 2 different IVF medication protocols in our practice to treat low responder patients with infertility: the "Microdose Leuprolide" protocol and the "Luteal Phase Ganirelix" protocol. We would like to conduct a randomized-controlled trial and randomize patients to one treatment group or the other to determine which medication protocol is more effective in treating infertility in this group of patients.
Women who demonstrate a suboptimal response to controlled ovarian hyperstimulation (COH) are
a challenge to treat with assisted reproductive technologies such as in vitro fertilization
(IVF). Such patients are often referred to clinically and in the medical literature as poor
responders. A variety of different protocols have been studied and used to treat these
patients. One protocol used to treat poor responders is the microdose leuprolide flare
protocol 1,2. This widely-used protocol was first described in 1997 by Schoolcraft et al. 1
The microdose leuprolide flare protocol is so named because the administration of a
gonadotropin-releasing hormone agonist (GnRH-a) in the early follicular phase causes an
initial rise in endogenous gonadotropins called a "flare" before it causes downregulation and
suppression of gonadotropins. Use of oral contraceptive pills (OCPs) in the preceding cycle
prevents corpus luteum formation which could be supported by exogenous GnRH-a in the
subsequent cycle. The microdose leuprolide flare protocol has been shown to be a safe and
effective protocol which may lead to decreased cycle cancellation rates and increased
clinical and ongoing pregnancy rates in poor responders 2,3.
The development of GnRH antagonists led to additional treatment options for poor responders
4. With GnRH antagonist use, suppression in the early follicular phase may be avoided. The
GnRH antagonist is then added in the late follicular phase to prevent an LH surge. This
protocol may enable a poor responder to recruit more follicles in the early follicular phase
and thus have a more optimal response to stimulation. A randomized-controlled multicenter
trial comparing the GnRH antagonist ganirelix to a GnRH agonist (Buserelin, intranasal
preparation) in patients using recombinant FSH (rFSH) showed that ganirelix was safe and
well-tolerated 5. They found that the mean duration of stimulation was 1 day shorter in the
ganirelix group and that this group used significantly less rFSH. A randomized-controlled
clinical trial of poor responders comparing the use of ganirelix to microdose leuprolide
acetate (GnRH-a) in patients undergoing COH for IVF found that the outcomes were similar in
both groups 6. There were no differences in total number of days of stimulation, amount of
rFSH used, peak estradiol levels, number of oocytes retrieved, fertilization rate,
implantation rate, or pregnancy rate. However, this study was limited by a small sample size.
Another randomized-controlled trial by Akman et al. 7 compared the use of microdose
leuprolide to GnRH antagonist (Cetrotide) in poor responders undergoing IVF. They found no
difference in implantation rates and clinical pregnancy rates but were also limited by a
small sample size.
In IVF cycles, poor responders often develop a dominant follicle and multiple small follicles
rather than multiple large follicles which is the goal of such treatment. In such cases, the
IVF cycle is often cancelled. The physiology behind such asynchronous follicular growth
during COH is poorly understood. Such discrepant growth may be the result of size differences
in early antral follicles 8. It is also possible that the premature FSH elevation that occurs
in the late luteal phase of the menstrual cycle plays a role in this process 9. FSH prevents
follicular atresia at the end of the luteal phase10. Some follicles are intrinsically more
sensitive to FSH and able to respond to low levels of this hormone than others. Given the
fact that larger follicles are often more FSH-responsive than small follicles, it makes sense
that exogenous gonadotropins may lead to worsening follicular asynchrony during COH 11.
It has recently been shown that the use of estradiol in the luteal phase of the preceding
menstrual cycle may facilitate growth of follicles in a coordinated fashion 8, 11. Fanchin et
al.11 prospectively studied 90 women who were undergoing IVF cycles using GnRH antagonists
and randomly assigned them to receive either 4 mg of oral micronized estradiol from cycle day
20 until day 2 of the next cycle or to serve as controls and receive no estradiol treatment.
They found that the group that received estradiol had significantly smaller follicles on day
8 of their cycle and had less of a discrepancy in follicle size.. The group that received
estradiol also had more follicles that were 16 mm or greater, more mature oocytes, and more
embryos than the control group. The clinical pregnancy rate was greater in the estradiol
group although this finding was not statistically significant (34 vs. 25%).
Recently, GnRH antagonists have also been shown to coordinate follicular size and subsequent
growth when used in the luteal phase of the preceding menstrual cycle 12,13. Dragesic et al.
13 developed a novel protocol for poor responders which incorporated both transdermal
estradiol (E2)and GnRH antagonist use in the luteal phase, followed by gonadotropin
stimulation in the follicular phase and the addition of a GnRH antagonist in the late
follicular phase. From this point on, this protocol will be referred to as the Luteal Phase
Ganirelix (LPG) Protocol. During the LPG protocol, subjects applied a 0.1 mg transdermal
estradiol patch on the 10th day after the LH surge and replaced this patch with a fresh 0.1
mg patch every other day. On the second day of patch use, subjects began taking daily
ganirelix acetate 0.25 mg subcutaneously for 3 days. Subjects presented for ultrasound on day
2 of menses for FSH, LH, E2 and an ultrasound and stimulation was started per protocol with
gonadotropins (rFSH and human menopausal gonadotropin (HMG)). Ganirelix was started when a
13mm follicle was measured on ultrasound, E2 exceeded 300 pg/mL, or on cycle day 7. Human
chorionic gonadotropin (hCG) was given for final oocyte maturation and oocyte retrieval was
performed 35-36 hours later. All embryo transfers were performed 72 hours after oocyte
retrieval. This retrospective study of 68 subjects compared their responses to the LPG
protocol with their responses to a prior IVF cycle protocol, which included microdose
leuprolide, low-dose leuprolide, and coflare protocols. They found that when patients used
the LPG Protocol they had significantly lower cycle cancellation rates, more oocytes
retrieved, more mature oocytes, more normally fertilized oocytes, and more embryos available
for transfer compared to their prior cycles. Patients did use more gonadotropins during the
LPG protocol and had more days of stimulation, although the latter was not statistically
significant.
Our goal in our proposed study is to determine whether the Microdose Leuprolide and LPG
Protocols are equally efficacious in treating poor responders.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A |